Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Equity Ratio (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Equity Ratio for 6 consecutive years, with 0.59 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 0.63% to 0.59 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.59, a 0.63% increase, with the full-year FY2025 number at 0.59, up 0.63% from a year prior.
  • Equity Ratio was 0.59 for Q4 2025 at GeneDx Holdings, down from 0.6 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.7 in Q4 2021 to a low of 3.23 in Q2 2021.
  • A 5-year average of 0.2 and a median of 0.6 in 2025 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: surged 240.87% in 2021, then decreased 26.22% in 2022.
  • GeneDx Holdings' Equity Ratio stood at 0.7 in 2021, then fell by 26.22% to 0.52 in 2022, then rose by 5.37% to 0.54 in 2023, then rose by 7.4% to 0.58 in 2024, then grew by 0.63% to 0.59 in 2025.
  • Per Business Quant, the three most recent readings for WGS's Equity Ratio are 0.59 (Q4 2025), 0.6 (Q2 2025), and 0.58 (Q4 2024).